Vitamin in the Crosshairs: Targeting Pantothenate and Coenzyme A Biosynthesis for New Antituberculosis Agents

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Tuberculosis (TB) treatment faces challenges from drug resistance and outdated therapies.
• Mycobacterium tuberculosis (Mtb) relies on coenzyme A (CoA) biosynthesis, an essential pathway validated in vitro and in vivo.
• The CoA pathway involves nine enzymes, synthesizing pantothenate and then CoA.

Purpose of the Study:

• To review literature on the structure, mechanism, inhibitors, and vulnerabilities of enzymes in the Mtb CoA biosynthesis pathway.
• To identify optimal targets within the CoA pathway for antitubercular drug discovery.
• To explore both single-enzyme inhibition and antimetabolite strategies.

Main Methods:

• Literature review of existing research on CoA biosynthesis in Mtb.
• Analysis of enzyme structures, mechanisms, and known inhibitors.
• Assessment of pathway enzyme vulnerabilities for drug development.

Main Results:

• The CoA biosynthesis pathway is essential for Mtb survival.
• Specific enzymes within the pathway have been identified as potential drug targets.
• Both direct enzyme inhibition and antimetabolite approaches show promise.

Conclusions:

• The CoA biosynthesis pathway offers significant opportunities for developing novel antitubercular drugs.
• Targeting specific enzymes or employing antimetabolite strategies could overcome current treatment limitations.
• Further research into CoA pathway enzymes is crucial for advancing TB drug discovery.